SCYNEXIS Announces $40.0 Million Private Placement
SCYNEXIS, a biotechnology company developing therapies for severe rare diseases, announced a private placement expected to raise $40 million upfront, with the potential additional $52.2 million from warrant exercises pending shareholder approval. The proceeds are intended to fund general corporate purposes and extend operational runway into mid-202…